TSTickerStarGet alerts
Company alerts/MEDS
MEDS company alerts

MEDS updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for MEDS. Subscribe to MEDS alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for MEDS alertsView companies
Official-source feed

Recent MEDS alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company updateOfficial company source

DataMeds AI terminates second amended and restated letter of intent

DataMeds AI terminated the second amended and restated letter of intent dated October 19, 2026 for an in-license or acquisition of intellectual property in exchange for DataMeds AI common stock, citing market conditions. The company said no shares will be issued in connection with the terminated LOI and that it owes no fees or obligations as a result of the termination. Its exclusive license with REBOOT and its PharmacyChain agreement with Datavault AI remain in force.

Read source-backed brief
Company newsOfficial company source

DataMEDS AI Establishes Health Lives Here Community Respiratory Program for Corexa Health Pharmacy Network

DataMEDS AI announced the establishment of its Health Lives Here Community Respiratory Program, which will be marketed to the 6,500+ independent pharmacies in the Corexa Health Pharmacy Network. The program aims to bring respiratory season best practices to community pharmacies and improve access to protein-based vaccines, diagnostics, and therapeutics. The program will first launch at Corexa Pharmacy in Lakeland, Florida in Q4 2026, with potential revenue streams from vaccine and antiviral dispensing, rapid tes...

Read source-backed brief
Company updateOfficial company source

DataMEDS AI Enters Amended and Restated LOI to License and Acquire IP Across Telehealth, Medical Drones and Healthcare Blockchain

DataMEDS AI, Inc. (NASDAQ:MEDS) announced on October 22, 2026 that it entered into an amended and restated non-binding letter of intent dated October 19, 2026 with Datavault AI Inc. (NASDAQ:DVLT), Data Health Partners, Inc. (including its REBOOT Health AI, Inc. subsidiary), EOS Technology Holdings, Inc., Scilex Holding Company (NASDAQ:SCLX) and HealthBridge Advisors, LLC to license and acquire intellectual property covering goal-driven prescription drug telehealth, medical drone delivery and healthcare blockchai...

Read source-backed brief
Company updateOfficial company source

DataMeds AI regains compliance with Nasdaq minimum stockholders' equity listing standard

On October 19, 2026, DataMeds AI, Inc. received notice from Nasdaq confirming the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), the $2,500,000 minimum stockholders' equity requirement. The Company had received a deficiency letter on April 13, 2026 after reporting stockholders' equity of $(12,447,801) in its Form 10-K for the fiscal year ended December 31, 2025, and had separately been cited for failing the $1.00 minimum bid-price requirement (bid-price compliance was regained on June 9, 20...

Read source-backed brief
Debt offeringSEC filing

DataMeds AI files 8-K covering REBOOT IP License Agreement and Nasdaq listing compliance

On October 13, 2026, DataMeds AI entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc., under which REBOOT granted the Company an exclusive U.S. license within a defined Field of Use (GLP-1 weight management via the Company's B2C business) to REBOOT's Licensed Patents and the REBOOT Health AI Platform. As consideration, the Company agreed to issue REBOOT 666,667 shares of common stock valued at $2,000,000 (subject to a $2,000,000 make-whole based on the 180-...

Read source-backed brief
Debt offeringSEC filing

DataMeds AI Licenses U.S. Rights to Reboot Health AI's Direct-to-Consumer GLP-1 Weight Management Platform

DataMeds AI, Inc. (NASDAQ: MEDS) entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. for U.S. direct-to-consumer rights to REBOOT's proprietary GLP-1 weight management care platform. The platform will be integrated into DataMeds' Health Lives Here mobile application as a subscription-based offering. REBOOT is an operating subsidiary of Data Health Partners, Inc., and the licensed IP includes six issued patents and six patent-pending applications. No transaction...

Read source-backed brief